负度数人工晶状体植入术治疗白内障合并超高度近视眼

目的　探讨超声乳化白内障吸除负度数人工晶状体植入术治疗白内障合并超高度近视眼的临床疗效。方法　对因白内障合并超高度近视眼行超声乳化白内障吸除负度数人工晶状体植入术的89例(126只眼)患者进行回顾性研究,记录术前眼轴长度和术后视力、屈光度数及其与预期屈光度数的偏差值(屈光度数偏差值),观察手术并发症和术后眼部情况。术后随访时间为6～25个月。结果　术前平均眼轴长度为32 45mm。术后最佳矫正视力≥0 2共106只眼(84 1%),≥0 5者共69只眼(54 8%)。术后屈光度数偏差值<±1 00D共71只眼(56 3%),<±2 00D共114只眼(90 5%)。术中仅1只眼晶状体后囊膜破裂;术后28只眼出现双眼干扰症状;后发性白内障15只眼,6只眼行激光晶状体后囊膜切开术;无视网膜和脉络膜脱离者,无眼压升高者。结论　超声乳化白内障吸除负度数人工晶状体植入术是治疗白内障合并超高度近视眼安全、有效的方法。     

晶状体眼前房型人工晶状体植入术矫正高度近视的临床研究

目的　探讨晶状体眼前房型人工晶状体植入术矫正高度近视的有效性和安全性。方法　对近视屈光度数为 - 7 0 0～ - 30 0 0D的 4 1例 (73只眼 )高度近视患者行晶状体眼前房型人工晶状体植入术 ,手术前、后检查患者的视力、屈光状态、眼压、角膜内皮细胞计数 ,裂隙灯下观察角膜、前房、瞳孔、透明晶状体、人工晶状体情况 ,检眼镜下观察眼底情况 ,房角镜下观察房角状况 ;并进行比较分析。术后随访时间 3个月。结果　 73只眼均成功植入前房型人工晶状体。裸眼视力术前为一尺指数至 0 2 ,术后 3个月为 0 1～ 1 0 ;最佳矫正视力术前为 0 0 5～ 1 0 ,术后 3个月为 0 1～ 1 0 ;术后3个月时最佳矫正视力均好于或等于术前。屈光度数术前为 - 7 0 0～ - 30 0 0D ,术后 3个月为 - 6 0 0～ +2 5 0D。术前与术后 3个月比较 ,角膜散光度数差异无显著意义 (t=1 75 1,P =0 0 82 ) ,眼压差异无显著意义 (t=1 181,P =0 2 4 0 )。平均角膜内皮细胞计数术前为 (2 6 80± 5 38)个 mm2 ,术后 3个月为 (2 5 14± 4 2 0 )个 mm2 ,较术前减少了 6 19% ,但差异无显著意义 (t=1 182 ,P =0 2 4 2 )。手术无严重并发症发生。结论　采用晶状体眼前房型人工晶状体植入术矫正高度近视 ,不仅手术操作简便 ,而且术后屈光状态具     

高度近视眼透明晶状体摘除联合人工晶状体植入术的临床观察

目的　探讨高度近视眼透明晶状体超声乳化吸除或囊外摘除联合人工晶状体植入术的安全性和有效性。方法　 33例 (4 7只眼 )高度近视眼 ,行超声乳化吸除联合折叠式人工晶状体植入术 2 8只眼 ,透明晶状体囊外摘除联合硬性人工晶状体植入术 1 9只眼。平均年龄 (4 8.3± 1 2 .6 )岁。术前矫正视力 0 .1 5～ 1 .0 ,平均近视度数 (-1 4 .2 2± 3.6 5 ) D,平均散光度数 (0 .97± 0 .82 ) D。随访半年以上。结果　术中 1只眼后囊膜破裂。术后半年 ,所有患者裸眼视力均提高 ,37只眼 (78.7% )裸眼视力≥ 0 .5 ,4 0只眼 (85 .1 % )矫正视力≥ 0 .5 ,平均近视度数 (- 1 .34± 0 .6 2 ) D,平均散光度数 (0 .84± 0 .87) D。术后晶状体后囊膜混浊 6只眼 (1 2 .8% ) ,视网膜脱离 1只眼。囊外摘除术者并发症多。结论　超声乳化透明晶状体摘除联合低度、负度数人工晶状体植入术是矫治高度近视眼安全、有效的手术方法 ,适应于不宜行角膜屈光手术的高度近视眼患者     

超声乳化透明晶状体吸除术治疗高度近视的临床研究

目的探讨超声乳化透明晶状体吸除联合人工晶状体植入术治疗高度近视的有效性和安全性.方法对26例(36只眼)高度近视患者行巩膜隧道切口超声乳化透明晶状体吸除联合人工晶状本植入术.平均年龄53.9岁,术前矫正视力0.2～1.0,平均近视度数(-13.1l±4.33)D,平均散光度数(0.72±0.91)D,平均眼轴长度(28.02±2.14)mm,平均植入人工晶状体屈光度数(+8.62±4.76)D.结果术后所有患者裸眼视力提高;25只眼(69.4%)裸眼视力≥0.5;27只眼(75.0%)矫正视力较术前提高.35只眼(97.2%)矫正视力≥0.5.术后平均近视度数(-1.51±0.60)D,平均散光度数(0.64±0.80)D.术后平均随访时间23.5个月.术后发生晶状体后囊膜混浊2只眼(5.6%),未见视网膜裂孔、视网膜脱离及黄斑囊样水肿.结论超声乳化透明晶状体吸除联合人工晶状体植入术是矫治高度近视安全、有效的方法,具有术后视力好、并发症少、预测屈光状态准确性及稳定性好等优点.     

有晶状体眼后房型人工晶状体植入矫正高度近视的临床评价

目的评价有晶状体眼后房型人工晶状体植入矫正高度近视的有效性、安全性及稳定性。方法选取1997年1月至2005年12月在我院就诊高度近视患者113例（216只眼）,平均年龄30岁,均在球周麻醉及表面麻醉下经3．2mm透明角膜切口植入后房型人工晶状体（ICLV2型15例,ICLV4,美国STAAR公司）,随访术前及术后1d、1周及1、3、6、12、24、36个月,随访内容包括裸眼视力、最佳矫正视力、角膜地形图、屈光度数、裂隙灯显微镜检查、眼压、角膜内皮计数等。术前检查等效球面屈光度数（17．78±3．88）D,平均随访18．2个月后观察屈光状态,24．3个月后观察术后并发症。结果所有手术均顺利进行,所有患者裸眼视力均有明显提高,最后一次随访等效球面屈光度数为（-1．00±1．40）D,与预期屈光度数差别±1．00D以内者191只眼（88．4％）,±0．50D以内者165只眼（76．4％）。术前屈光度数在-20．00D以下的有151只眼,与预期屈光度数差别±1．00D以内者145只眼（96．0％）,±0．50D以内者128只眼（84．8％）。随访期间屈光度数差异无统计学意义（P〉0．05）,术后1年最佳矫正视力提高1行及以上168只眼（77．8％）,4只眼（1．85％）下降1行。4只眼（1．85％）发生需手术治疗瞳孔阻滞性青光眼,3只眼（1．39％）发生晶状体前囊下混浊,均行人工晶状体取出,晶状体摘除及人工晶状体植入术,术后最佳矫正视力无下降。结论有晶状体眼后房型人工晶状体植入矫正高度近视具有有效性、安全性及稳定性。（中华眼科杂志,2007,43：1000-1004）     

有晶状体眼人工晶状体植入矫正高度近视

目的观察有晶状体眼前房型人工晶状体植入治疗高度近视的临床效果。方法对近视屈光度为-8．50D～-32．00D的22例（40眼）高度近视行有晶状体眼前房角支撑袢型人工晶状体植入术，连续观察1年。结果40眼均成功植入前房型人工晶状体。裸眼视力术前数指／20cm～0．08，术后12月0．2～1．2；最佳矫正视力术前0．2～1．0，术后0．2～1．2。术后12月时最佳矫正视力均好于或等于术前；术后不同频段的对比敏感度和眩光对比敏感度都较术前改善。结论有晶状体眼前房型人工晶状体植入矫正高度近视疗效好，视力恢复快，屈光状态稳定。     

准分子激光原位角膜磨镶术治疗超高度近视远期疗效分析

目的探讨准分子激光原位角膜磨镶术(LASIK)治疗超高度(等效球镜度数>-10.00 D)近视的远期效果和安全性.方法对99例(173只眼)超高度近视行LASIK矫正,术前屈光度数-10.00～-23.50 D,平均(-13.7±3.6)D(等效球镜),其中-15.00 D以上41只眼.常规行裂隙灯显微镜、三面镜眼底检查、OrbscanⅡ眼前段分析系统、眼压、A超、角膜测厚、电脑验光、散瞳检影、主观验光等检查.术后随访18个月以上.结果术后18个月时裸眼视力≥0.5者148只眼(85.6%),最佳矫正视力高于或等于术前最佳矫正视力者147只眼(84.4%),未见术后最佳矫正视力较术前最佳矫正视力低于2行以上的眼;屈光度数稳定在±1.00 D以下者109只眼(63.0%),术前屈光度数在-14.75 D以下和-15.00 D以上达到±1.00 D内者的百分数分别为73.5%(97只眼/132只眼)和29.3%(12只眼/41只眼).术后角膜后表面前移,术后3个月时后表面顶点距理想球面的距离为(0.069±0.031)mm,18个月为(0.065±0.025)mm,均大于术前的(0.029±0.010)mm;角膜微皱褶2只眼,诉暗视力下降眩光6例(10只眼).结论 LASIK矫正超高度近视有效安全,同时在选择手术适应证方面应谨慎从之.对于屈光度数太高而角膜厚度偏薄者行LASIK应慎重,可考虑其他方法矫正如晶状体屈光手术或联合手术.(中华眼科杂志,2004,40816-818)     

有晶状体眼后房型人工晶状体植入术矫正高度近视

探讨有晶状体眼后房型人工晶状体（phakic intraocular lens,PIOL）植入术矫正高度近视的有效性和安全性。 方法：本研究中高度近视患者17例33眼,术前屈光度-8.00～-24.00 (平均-15.46±6.26)D,眼轴长度25.33～33.77(平均30.22±2.55)mm。33眼植入后房型人工晶状体也称植入性接触镜（implantable contact lens,ICL& toric implantable collamer lens, TICL）。其中,22眼植入ICL,11眼植入TICL。术后观察视力、屈光度、眼压、人工晶状体位置等。 结果：所有病例均成功植入后房型人工晶状体。术后1wk,所有手术眼达到或超过术前最佳矫正视力,屈光度和眼压稳定。 结论：有晶状体眼后房型人工晶状体植入术治疗高度近视安全有效,适用屈光度范围广,术后屈光度稳定,视觉质量提高     

有晶状体眼后房散光型IOL植入矫正高度近视散光

目的：评价有晶状体眼后房散光型人工晶状体(TICL)植入术矫治高度近视散光的临床效果。

方法：选自2009-10/2011-11接受TICL植入的高度近视散光患者30例50眼,术前平均屈光度球镜-10.75±2.65D,柱镜-2.85±0.75D。随访观察术后3mo～2a裸眼视力、最佳矫正视力、屈光度、内皮细胞计数等情况,分析并发症的发生情况。

结果：术后裸眼视力：0.5～1.2(平均0.75±0.34)。术前最佳矫正视力：0.3～1.0(平均0.58±0.35),术后最佳矫正视力0.6～1.2(平均0.78±0.35)。达到术前矫正视力20眼(40%),超过术前最佳矫正视力30眼(60%),随访3mo～2a,视力无明显变化。术后屈光度数平均球镜-0.52±0.35D,柱镜0.52±0.25D。角膜内皮细胞计数术前3 026±250个/mm²,术后3mo为3 023±246个/mm²,差异无统计学意义(P<0.05)。未见严重影响视力的并发症。

结论：TICL植入矫治高度近视散光安全有效,是高度近视散光患者的理想治疗方法。对眼内的长期影响需要进一步观察。     

有晶状体眼后房型人工晶状体植入治疗高度近视临床观察

目的评价有晶状体眼后房型人工晶状体(ICL)植入术矫治高度近视的临床效果。方法自2009年2月至2011年2月接受ICL植入的高度近视患者82例(160只眼),术前平均屈光度球镜(-13.65±4.25)D,柱镜(-2.65±0.75)D。观察术后裸眼视力、最佳矫正视力、屈光度、内皮细胞计数等情况,分析并发症的发生情况。结果术后裸眼视力:0.5～1.0,平均0.78±0.32。术前最佳矫正视力:0.3～1.0,平均0.59±0.36,术后最佳矫正视力0.79±0.30。达到术前矫正视力92只眼(57.5%),超过术前最佳矫正视力68只眼(42.5%),随访6个月至2年,无明显变化。术后屈光度数平均球镜(-0.75±0.65)D,柱镜(-0.55±0.25)D。角膜内皮细胞计数术前(3126±260)个/mm2,术后6个月为(3069±308)个/mm2,差异无统计学意义。结论有晶状体眼后房型人工晶状体(ICL)植入矫治高度近视及超高度近视安全有效,是高度近视患者的理想治疗方法。     

激光性角膜手术与眼内屈光手术矫治超高度近视眼

目的:评价及探讨矫治超高度近视眼的各类屈光手术的有效性、稳定性和安全性。方法:随机选择临床中观察到的超高度近视患者行各类屈光手术者108眼,近视范围-10.00～-24.50D,术前屈光度平均为(-12.25±1.53)D,散光平均为(-1.52±0.55)D;手术方式的选择:(1)I组52眼,行LASIK术:(2)II组23眼,行透明晶状体超声乳化摘除加后房型人工晶状体植入术。(3)III组33眼行有晶状体眼虹膜固定型人工晶状体植入术。术后随访观察平均6mo,主要观察术后裸眼视力、最佳矫正视力、屈光度、眼压及眼前段、眼底情况。结果:三组术后裸眼视力均比术前提高,术后裸眼视力≥0.5者分别是42眼(80.8%),20眼(87.0%),28眼(84.8%),术后屈光度分别为(-2.10±2.38)D,(-1.75±1.33)D,(0.83±1.16)D,主要并发症I组术后6mo黄斑出血1眼,II组术后15mo视网膜脱离1眼,III组平均角膜内皮细胞丢失率为4.5%。结论:对于超高度近视,晶状体性屈光手术效果优于LASIK术。对超高度近视行屈光手术,要根据患者年龄,眼部情况,手术医师的技术等,选择安全、有效、稳定性好的手术。     

Visual improvement in high myopic amblyopic adult eyes following phakic anterior chamber intraocular lens implantation

PURPOSE: To evaluate the efficacy and safety of angle-supported phakic anterior chamber intraocular lenses in amblyopic adult eyes with very high myopia. METHODS: We evaluated 12 eyes in nine patients with very high myopic amblyopia who received angle-supported phakic intraocular lenses (Phakic 6H) and followed them for more than six months. Uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), and complications were evaluated. A satisfaction score was rated by patients using a 5-point (1-5) numeric scale. RESULTS: The mean age of patients was 37.3 +/- 9.4 years, ranging from 29 to 59 years old. The preoperative mean refraction (spherical equivalent, SE) was -20.10 +/- 5.41 diopters (D). The postoperative mean refraction (SE) was -1.75 +/- 0.76 D at six months. The postoperative BCVA improved an average 3.92 +/- 1.24 lines over preoperative values, and mean endothelial cell loss was 8.9% at six months. Development of cataracts, glaucoma, and pupil abnormalities were not demonstrated in any case during the study. The patients were all very satisfied, as the average satisfaction score was 4.3. CONCLUSIONS: This study indicates that angle-supported phakic anterior chamber intraocular lens implantation may be an effective surgical alternative for the correction of amblyopic adult eyes with very high myopia. However, long-term evaluation is necessary to assess possible complications and long-term safety.     

虹膜夹型有晶状体眼人工晶状体矫治高度近视眼的初步报告

目的研究虹膜夹型有晶状体眼人工晶状体（ICPIOL）矫治高度近视眼的安全性和有效性。方法高度近视眼患者13例（25只眼）,等效球镜度数（SE）（-15．63±3．51）D植入ICPIOL。术后随访1年,观察手术前后的视力、屈光状态、眼压、角膜、前房、瞳孔、ICPIOL和晶状体、眼底情况,并进行比较。结果与术前比较,术后1d、7d及1、3、6、12个月的裸眼视力（UCVA）、最佳矫正视力（BCVA）和SE显著改善。术后1年时,所有眼UCVA均1〉0．5,其中〉10．8有71．43％;BCVA未见下降,95．24％提高≥2行,4．76％提高1行;所有眼的屈光状态均稳定在±2．00D,其中±0．50D有71．43％,±1．00D有85．71％。术后1年角膜内皮细胞丢失无统计学意义。除了7只眼术中在夹持虹膜固定ICPIOL时有轻度虹膜脱色素,1只眼主切口渗漏于术后第2天重新缝合外,未见其他并发症发生。结论ICPIOL矫治高度近视术后1年内安全、有效。远期效果尚待进一步观察。     

有晶状体眼前房型人工晶状体植入矫治高度近视临床观察

目的:观察有晶状体眼Verisyse前房虹膜夹型人工晶状体植入矫治高度近视术后的视力、屈光状态以及相关并发症,评价其临床应用价值。方法:自2006-07/2008-07接受Verisyse人工晶状体植入术的32例48眼,术前平均球镜当量-15.65±3.41D。统计术后6mo;1a裸眼视力,最佳矫正视力、屈光度、内皮细胞计数,分析并发症的发生情况。结果:术后裸眼视力:0.4～1.0,平均0.75±0.34。术前最佳矫正视力:0.3～1.0,平均0.58±0.27,术后最佳矫正视力0.64±0.30。达到术前矫正42眼(87.5%),超过术前最佳矫正视力14眼(29.2%),随访6mo;1a,无明显变化。术前屈光平均球镜当量-15.65±3.41D;术后屈光度数平均球镜当量-1.58±2.47D。角膜内皮细胞计数术前(3108±265)个/mm2,术后6mo为(3054±317)个/mm2,差异无统计学意义。未见威胁视力的并发症。结论:有晶状体眼前房虹膜夹型人工晶状体植入矫治超高度近视安全有效,术后屈光效果令人满意。对眼内的长期影响需要进一步观察。     

Artisan iris-claw phakic intraocular lens followed by laser in situ keratomileusis for high hyperopia

PURPOSE: To evaluate safety, efficacy, predictability, stability, complications, and patient satisfaction after Artisan phakic intraocular lens (IOL) implantation followed by laser in situ keratomileusis (LASIK) for the correction of high hyperopia. SETTING: Instituto Oftalmólogico de Alicante, Alicante, Spain. METHODS: This prospective trial included 39 eyes with a mean preoperative spherical equivalent (SE) of 7.39 diopters (D) +/- 1.30 (SD) and a cylinder between 0 and -4.25 D. The Artisan iris-fixated phakic IOL (Ophtec) for hyperopia was implanted, and LASIK was performed 6 to 8 months later. The best corrected visual acuity (BCVA), uncorrected visual acuity (UCVA), refraction, endothelial cell loss (ECL), endothelium morphologic analysis, and patient satisfaction were recorded. The minimum follow-up was 12 months. RESULTS: At 1 year, 37 eyes (94.9%) were within +/-1.00 D of emmetropia and 31 eyes (79.5%) were within +/-0.50 D. Thirty-five eyes (89.7%) achieved a UCVA of 0.5 or better. There was a statistically significant decrease in BCVA after phakic IOL implantation, but this effect was corrected after LASIK. Nine eyes (23.1%) lost 1 line of BCVA; 7 eyes (17.9%) gained at least 1 line. One eye (2.6%) showed a change in SE greater than 1.0 D over the follow-up period. The mean ECL was 10.9%, but morphologic analysis suggested no additional damage caused by LASIK over that produced by phakic IOL surgery. Overall patient satisfaction was high. CONCLUSIONS: The combination of Artisan phakic IOL implantation and LASIK safely, predictably, and effectively reduced high hyperopia. A loss of 1 line of BCVA should be expected in about one third of eyes implanted with this IOL. Halos and glare at night remain a potential problem.     

AcrySof phakic angle-supported intraocular lens for the correction of high to extremely high myopia: one-year follow-up results

AIM: To assess the safety, efficacy and predictability of the AcrySof phakic angle-supported intraocular lens (IOL) (Alcon Inc., U.S.A.) for correction of high-to-extremely high myopia in adults. METHODS: In this prospective study performed in Tianjin Medical University Eye Center & College of Optometry, Tianjin, China, 25 eyes of 13 patients were implanted with AcrySof phakic angle-supported IOLs and followed for 1 year postoperatively. Preoperative manifest refractive sphere was (-12.08±2.44) diopters (D) and cylinder was (-1.35±0.62)D. Visual acuity, predictability and stability of manifest refraction spherical equivalent (MRSE), adverse events, and endothelial cell density were analyzed during 1-year of follow-up. RESULTS: After 1 year of follow-up, no eyes lost≥1 line (best spectacle-corrected visual acuity)BSCVA; an uncorrected visual acuity (UCVA) of 20/20 or better was achieved in 60% of eyes; 100% had an UCVA of 20/40 or better; a BSCVA of 20/30 or better was achieved by 100% of eyes; 84% had a BSCVA of 20/20 or better. The overall mean percentage change in endothelial cell density 1 year after surgery was (-0.27±3.60)%. Two eyes (8%) had increased intraocular pressure (IOP) on the day of surgery. No pupil ovalization, pupillary block, or retinal detachment events were observed. CONCLUSION: After 1 year of follow-up, the implantation of AcrySof phakic angle-supported IOL is proved to be safe, effective and predictable with minimal complications in patients with high-to-extremely high myopia. Due to the limitation of visiting time, long-term of clinical investigation is necessary to verify the safety and efficacy of this IOL.     

Angle-supported phakic intraocular lenses followed by laser-assisted in situ keratomileusis for the correction of high myopia

To evaluate the safety, effectiveness, predictability, and stability of the combination of angle-supported phakic intraocular lens (PIOL) implantation and laser-assisted in situ keratomileusis (LASIK) for the correction of high myopia.Noncomparative interventional case series.At the Instituto Oftalmológico de Alicante, Spain, 24 consecutive eyes of 12 patients with a preoperative spherical equivalent between -9 and -26 diopters were studied. Implantation of an angle-supported PIOL was done as the first surgery. Laser-assisted in situ keratomileusis was performed at least 6 months after PIOL surgery, once stability of topography and refraction were proved. Main outcome measures were uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), refraction, applanation tonometry, and corneal endothelial study (cell density, hexagonality, and coefficient of variation), with a minimum follow-up of 12 months after LASIK.The mean spherical equivalent refraction decreased from -15.17 +/- 5.15 diopters before PIOL implantation to -1.33 +/- 1.18 diopters after PIOL surgery and to 0.01 +/- 0.53 12 months after LASIK. Uncorrected visual acuity was 0.39 +/- 0.12 after PIOL surgery, increasing to 0.65 +/- 0.23 12 months after LASIK. There was an increase in 20/40 or better UCVA from 16.6% after PIOL surgery alone to 83.3% after addition of LASIK. At final follow-up, spherical equivalent was within +/- 1 diopter of emmetropia in 22 eyes (91.7%) and in 18 eyes (75%) within +/- 0.50 diopters. Vector analysis demonstrated that astigmatic components of refractive error after PIOL surgery were well corrected by LASIK. At final follow-up the mean endothelial cell loss was 4.88% (P <.001). There were no statistically significant differences between mean endothelial cell count, percentage of hexagonality, or coefficient of variation before LASIK and 12 months after LASIK, suggesting that no corneal endothelial damage was produced by LASIK itself. No sight-threatening complications occurred through the follow-up period.The combination of angle-supported PIOL implantation and LASIK appears to be a safe, effective, predictable, and stable procedure for the correction of high myopia. This paper emphasizes the benefits of adding LASIK to the use of PIOL alone.     

有晶状体眼的人工晶状体植入术

目的观察有晶状体眼的人工晶状体（ICL）植入术矫正高度近视的临床效果。方法22例（39只眼）高度近视患者,近视度数-7．00- -23．00 D,平均（-11．48±3．70）D。术前裸眼视力（UCVA）0．02-0．3,平均0．05±0．03,术前最佳矫正视力（BCVA）0．8-1.2,平均0．90±0．27;角膜内皮密度2000-3961个／mm^2,平均（2735．13±464．50）个／mm^2;所有患者随访12个月。结果术后裸眼视力显著提高,术后1d,1周11、3、6和12个月的裸眼视力较之术前差异有统计学意义（P=0．0000）。结论有晶状体眼的人工晶状体植入术治疗高度近视临床效果确切,特别适宜于无法选择角膜屈光手术者,其远期并发症还有待进一步观察。     

有晶状体眼Verisyse人工晶状体植入术矫正超高度近视眼

目的：探讨有晶状体眼Verisyse人工晶状体植入术矫正超高度近视眼的有效性、安全性及可预测性。 方法：超高度近视眼患者10例13眼植入Verisyse人工晶状体。术后观察患者的视力、屈光度数、眼压、角膜内皮细胞计数、对比敏感度、晶状体位置、眩光敏感度、手术并发症及视觉不良症状。 结果：术后患者裸眼视力及最佳矫正视力均有明显的提高。术后3mo及术后1a患者最佳矫正视力≥0.5者占100%,患者最佳矫正视力≥0.8者占85%。患者术后屈光度稳定,术后1mo～1a,屈光状态变化无明显差异。患者术后1a内各时间点眼压均无明显异常升高。术后角膜内皮计数均有所下降,但其差异无统计学意义。术后3mo时,各频段对比敏感度和眩光敏感度较术前均明显提高。Verisyse人工晶状体与角膜内皮和晶状体均保持了有效的安全距离。术后3mo时,2眼可见Verisyse人工晶状体表面炎性反应物沉积,1眼瞳孔呈轻度椭圆形。患者均无明显不适,满意程度较高。 结论：Verisyse人工晶状体矫正超高度近视眼具有良好的有效性、安全性及可预测性,是补充角膜屈光手术不足的有效眼内屈光手术,但其远期效果有待进一步观察。     

Ultrasonographic measurement of induced myopia associated with capsular bag distention syndrome

OBJECTIVE: To determine the causes of postoperative myopia associated with capsular bag distention syndrome (CBDS) and characterize the associated findings. DESIGN: Prospective, multicenter, nonrandomized, comparative (self-controlled) trial. PARTICIPANTS: Six eyes from six patients had CBDS develop after phacoemulsification and posterior chamber intraocular lens implantation. METHODS: Keratometric values, axial length, visual acuity, and manifest refraction were assessed in each eye. Using 20-MHz (I3SYSTEM-ABD, Innovative Imaging Inc, Sacramento, CA) and 50-MHz (Ultrasound Biomicroscope, Zeiss Humphrey Systems, Dublin, CA) ultrasonographic probes, images and measurements of the anterior segment were obtained. After neodymium:yttrium-aluminum-garnet (Nd:YAG) capsulotomy, these measures were repeated and correlated with predicted and actual refractive changes. MAIN OUTCOME MEASURES: Uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), manifest refraction, and anterior chamber depth before and after treatment of CBDS. RESULTS: Although intended postoperative refraction averaged -0.58 diopters (D) (range, -0.12 to -1.63 D), eyes with CBDS had an average spherical equivalent refraction of -2.35 D (range, +0.13 to -4.50 D), P < 0.05 (one-tailed, paired t test). BCVA averaged 20/24 (range, 20/15-20/40-1), but UCVA averaged 20/133 (range, 20/60 to 20/400). Average distance from the corneal surface to the anterior intraocular lens (IOL) optic surface was 3.55 mm in eyes with CBDS, and 4.30 mm after Nd:YAG capsulotomy. Posterior movement of the IOL optic after capsulotomy accounted for 1.23 D of hyperopic shift or 82% of the CBDS-induced myopia. Treatment of CBDS resulted in both improved UCVA and BCVA. Nd:YAG capsulotomy also released the colloidal suspension within the capsular bag posterior to the IOL optic. The incidence of CBDS was 0.3% in one of the practices reviewed. CONCLUSIONS: Capsular bag distention syndrome includes unexpected myopia and poor UCVA after cataract surgery with lens implantation in cases involving a continuous capsulorhexis. A dramatic posterior distention of the posterior capsule is observed, as well as anterior chamber shallowing, tight apposition of the iris to the IOL, and anterior bowing of the iris. A slightly turbid colloidal suspension behind the IOL implant and late posterior capsular fibrosis are also observed. Timely treatment of CBDS can correct unwanted myopia, improve UCVA and BCVA, and restore normal anatomic relationships in the eye.